Meeting
2018 ASCO Annual Meeting
Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).
Authors
Julien Taieb
Sorbonne Paris Cité, Paris Descartes University, Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, Paris, France
Julien Taieb , Yves Rinaldi , Anne-Laure Pointet , Emilie Barbier , Faiza Khemissa , Alain Gratet , Laurent Miglianico , Hortense Laharie-Mineur , Karine Bouhier-Leporrier , François Ghiringhelli , Anne Thirot Bidault , Patrick Texereau , Romain Coriat , Eric Terrebonne , Marie-Claude Gouttebel , David Malka , Come Lepage , Jean-Baptiste Bachet
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT02827201
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4107)
DOI
10.1200/JCO.2018.36.15_suppl.4107
Abstract #
4107
Poster Bd #
296
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Daniel John Renouf
Poster
2020 ASCO Virtual Scientific Program
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.
First Author: Shintaro Nakano
Poster
2017 Gastrointestinal Cancers Symposium
A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC).
First Author: Philippa Corrie
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.
First Author: Michele Reni